Fri, Aug 29, 2014, 3:45 PM EDT - U.S. Markets close in 15 mins.


% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

  • jgmtruth jgmtruth Jan 24, 2013 5:03 PM Flag

    Dr. Furman on Trials Examining Ibrutinib's Safety in CLL

    Richard R. Furman, MD
    Published Online: Friday, January 18, 2013 Richard R. Furman, MD, director of the Chronic Lymphocytic Leukemia (CLL) Research Center and a senior member of the Center for Lymphoma and Myeloma at the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia (CLL).

    A preliminary phase II trial examining ibrutinib as a monotherapy in refractory populations found impressive response rates, states Furman. However, in this population there was a great deal of toxicities, including secondary myelodysplasia and AML, Richter's transformation, or infections. These added toxicities were due to the large amount of prior therapies that patients had received, Furman explains.

    These toxicities prompted a phase II study looking at ibrutinib in previously untreated patients with CLL. In General, Furman explains, this trial did not find any clear ibrutinib-associated toxicities. Overall, the trial found the agent to be well tolerated and reasonably safe.

    The phase III trial examining ibrutinib is currently underway. Furman is optimistic that this trial will lead to the FDA approval of ibrutinib in CLL.

    Sentiment: Strong Buy

124.27+0.32(+0.26%)3:45 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.